NCT04701476 TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
| NCT ID | NCT04701476 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Teclison Ltd. |
| Condition | Colorectal Cancer; Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2021-05-20 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 110 participants in total. It began in 2021-05-20 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Eligibility Criteria
Inclusion Criteria: * Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations * mCRC progressed on at least two lines of standard chemotherapy; or * NSCLC progressed on chemotherapy and an immune checkpoint inhibitor * Measurable disease * ECOG 0-1 * At least 4 weeks from prior chemotherapy and free from chemo-related toxicity * Adequate organ function Exclusion Criteria: * Prior organ transplantation * Liver metastasis more than 50% * Oxygen saturation less than 92% in room air * Prior autoimmune disorder * CNS metastasis * Major GI bleeding in the last 2 months
Contact & Investigator
Ray Lee
STUDY DIRECTOR
Teclison Limited
Frequently Asked Questions
Who can join the NCT04701476 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer; Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04701476 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT04701476 currently recruiting?
Yes, NCT04701476 is actively recruiting participants. Contact the research team at ray.lee01@teclison.com for enrollment information.
Where is the NCT04701476 trial being conducted?
This trial is being conducted at Orange, United States, Hsinchu, Taiwan, Taichung, Taiwan.
Who is sponsoring the NCT04701476 clinical trial?
NCT04701476 is sponsored by Teclison Ltd.. The principal investigator is Ray Lee at Teclison Limited. The trial plans to enroll 110 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.